Home / Stocks / CAI

Caris Life Sciences (CAI, Biotechnology) Stock Valuation & Fair Value No P/E valuation

Caris Life Sciences (CAI, Biotechnology) trades at a blended P/E of 7,372.6, trading without a historical P/E to compare against, with a forward growth estimate above 100% and a PEG of 9.04.

This company has no P/E to compare against its own history, so tickerseer publishes no valuation rating for it. The figures below are unaffected.

DATA AS OF 2026-10-12
Blended P/E
7,372.6
Normal P/E
—
PEG
9.04
Fwd growth
>100%
Div yield
0.0%
RSI (14)
55.9
Neutral
Technical context
  • Price $29.70 at the 2026-10-09 close, 0.1% below the 20-day average ($29.72) and 15.4% above the 50-day ($25.73).
  • RSI (14) at 55.9.
  • 52-week range $14.55 to $32.27: the price is 8.0% below the high and 104.1% above the low.

The Street vs SeerForecast

Wall Street's mean price target for CAI is $30.38 across 13 analysts, 2.3% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: we publish none, because it has no P/E to compare against its own history. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

Price and rating by weekClose moved +89.5 percent from 2026-07-31 to 2026-10-09, with 1 rating change over 24 recorded weeks.2026-07-31: No P/E valuation, close 15.67, recalculated for the week of 2026-07-312026-07-31: No P/E valuation, close 15.67, recorded live 2026-08-032026-08-07: No P/E valuation, close 22.74, recalculated for the week of 2026-08-072026-08-07: No P/E valuation, close 22.74, recorded live 2026-08-102026-08-14: No P/E valuation, close 21.80, recalculated for the week of 2026-08-142026-08-14: No P/E valuation, close 21.80, recorded live 2026-08-172026-08-21: No P/E valuation, close 26.27, recalculated for the week of 2026-08-212026-08-21: No P/E valuation, close 26.27, recorded live 2026-08-242026-08-27: No P/E valuation, close 26.38, recalculated for the week of 2026-08-272026-08-28: No P/E valuation, close 25.63, recalculated for the week of 2026-08-282026-08-28: No P/E valuation, close 25.63, recalculated for the week of 2026-08-302026-08-28: No P/E valuation, close 25.63, recorded live 2026-08-312026-09-04: No P/E valuation, close 25.07, recalculated for the week of 2026-09-052026-09-04: No P/E valuation, close 25.07, recorded live 2026-09-072026-09-11: No P/E valuation, close 24.34, recalculated for the week of 2026-09-122026-09-11: No P/E valuation, close 24.34, recorded live 2026-09-142026-09-18: No P/E valuation, close 29.98, recalculated for the week of 2026-09-192026-09-18: No P/E valuation, close 29.98, recorded live 2026-09-212026-09-25: No P/E valuation, close 31.98, recalculated for the week of 2026-09-262026-09-25: No P/E valuation, close 31.98, recorded live 2026-09-282026-10-02: No P/E valuation, close 28.30, recalculated for the week of 2026-10-032026-10-02: No P/E valuation, close 28.30, recorded live 2026-10-052026-10-09: No P/E valuation, close 29.70, recalculated for the week of 2026-10-102026-10-09: No P/E valuation, close 29.70, recorded live 2026-10-12$20$25$30Jul 31Aug 18Sep 4Sep 21Oct 9
No P/E valuationNo P/E valuation

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 0.0not availableNo P/E valuation (recalculated)
2026-09-26P/E 0.0not availableNo P/E valuation (recalculated)
2026-10-12P/E 7,372.6not availableNo P/E valuation ← now
Show all 24 weeks
WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 0.0not availableNo P/E valuation (recalculated)
2026-08-03P/E 0.0not availableNo P/E valuation
2026-08-07P/E 0.0not availableNo P/E valuation (recalculated)
2026-08-10P/E 0.0not availableNo P/E valuation
2026-08-14P/E 0.0not availableNo P/E valuation (recalculated)
2026-08-17P/E 0.0not availableNo P/E valuation
2026-08-21P/E 0.0not availableNo P/E valuation (recalculated)
2026-08-24P/E 0.0not availableNo P/E valuation
2026-08-27P/E 0.0not availableNo P/E valuation (recalculated)
2026-08-28P/E 0.0not availableNo P/E valuation (recalculated)
2026-08-30P/E 0.0not availableNo P/E valuation (recalculated)
2026-08-31P/E 0.0not availableNo P/E valuation
2026-09-05P/E 0.0not availableNo P/E valuation (recalculated)
2026-09-07P/E 0.0not availableNo P/E valuation
2026-09-12P/E 0.0not availableNo P/E valuation (recalculated)
2026-09-14P/E 0.0not availableNo P/E valuation
2026-09-19P/E 0.0not availableNo P/E valuation (recalculated)
2026-09-21P/E 0.0not availableNo P/E valuation
2026-09-26P/E 0.0not availableNo P/E valuation (recalculated)
2026-09-28P/E 0.0not availableNo P/E valuation
2026-10-03P/E 0.0not availableNo P/E valuation (recalculated)
2026-10-05P/E 0.0not availableNo P/E valuation
2026-10-10P/E 0.0not availableNo P/E valuation (recalculated)
2026-10-12P/E 7,372.6not availableNo P/E valuation ← now

Frequently asked questions

Is Caris Life Sciences stock overvalued?

At a blended P/E of 7,372.6, Caris Life Sciences has no historical normal P/E on record to compare that against, with a PEG of 9.04 on forward growth above 100%. tickerseer therefore publishes no valuation rating for it.

What is Caris Life Sciences's fair value and PEG?

Caris Life Sciences trades at a blended P/E of 7,372.6, a PEG of 9.04, and a forward growth estimate above 100%.

Has tickerseer's rating of Caris Life Sciences changed?

tickerseer has published no valuation rating since 2026-07-31, because this company has no P/E to compare against its own history.

What is the analyst price target for Caris Life Sciences?

The mean Wall Street price target for Caris Life Sciences is $30.38 across 13 analysts, 2.3% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track CAI free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.